- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03516162
Linking Digital Smartphone Behaviour With Brain Function (SmartSurgery)
Linking Day-to-day Digital Behaviour Captured on the Smartphone With Brain Function in Patients Undergoing Brain Surgery - the "Smart Surgery" Study
This study will thus examine daily behaviour based on smartphone use and link it to the neurological and neuropsychological status as well as to neuroradiological studies that are part of the clinical routine. The study will examine behaviour changes before and after surgery, and how this change in measured behaviour with the smartphone relates to today's "gold standard", namely professional neuropsychological examination and quantification of brain damage on imaging studies (MRI).
This study is a proof-of-principle study that intends to build the basis for larger future observational studies on patients with focal or diffuse brain pathologies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pathologies of the central nervous system (CNS), as well as their surgical treatment, may interfere with the physiological and behavioural functions of the human brain. Commonly, before and after surgical treatment, the neurosurgeon examines the patient carefully for neurological deficits and additionally asks neuropsychologists to evaluate higher cognitive functions. These examinations, however, only represent the situation at a given point in time, and currently longitudinal or continuous evaluation of physiological and behavioural functions of the human brain is highly limited. Furthermore, in the conventional examinations the complex human behaviour is reduced to very simplified scores (e.g. the NIHSS for neurological or MoCA for neuropsychological functioning). Fluctuations in physiological and behavioural functions are very likely, but are unlikely to be captured with current evaluations at single (discrete) pre- and postoperative points in time. To date, "on-line" continuous evaluation of brain function in patients undergoing (potentially risky) neurosurgical procedures has not been established.
The touchscreen interface of smartphones offers a fresh avenue to capture day-to-day behaviour (engagement of finger tips) by exploiting the technology intrinsic to a smartphone. For instance, the speed of touchscreen use, the distinct behavioural contexts (compartmentalised into Apps) and the corresponding habits can be seamlessly and non-obtrusively captured. More importantly, compared with current discrete approaches of evaluation, this continuous approach can account for - and even exploit - the natural fluctuations in brain functions.
Nevertheless, behavioural data from touchscreens is new to scientific exploration and various fundamental questions remain to be answered, such as what are the basic statistical features of smartphone behaviour, how does this behaviour vary from one day to another, and how does this behaviour reflect basic demographic information? This gap in our understanding of smartphone behavioural data also implies that the exact statistical methods to be employed may need to undergo adjustments. For instance, the common central tendency measure of the sample mean may be highly unstable if the parameter/s occupy a power-law distribution rather than a Poisson or Gaussian distribution. In summary, ever-new exploration of the neuroscience of touchscreen behaviour must trigger the right choice of analytical and statistical methods.
The focus of this study is laid on patients with pathologies of the CNS. The investigators aim to examine both patients with diffuse and focal pathologies. In order to study diffuse pathologies, the investigators will include patients with hydrocephalus. In order to study focal pathologies, the investigators will include patients with brain tumours or arteriovenous malformations (AVMs) - which are localised and described using clinical neuroimaging. Patients will be examined before and after a neurosurgical procedure.
At the "UniversitätsSpital Zürich", both patients with hydrocephalus that are scheduled for ventriculo-peritoneal (VP)-shunting and patients with brain tumours/AVMs that are scheduled for microsurgical resection routinely undergo a neurosurgical, neuropsychological and neuroradiological examination (by MRI) preoperatively and at 3 months postoperative (for clinical purpose). Patients that agree to participate in this study will install a free App (programmed by the University of Zurich (UZH) spin-off QuantActions and freely available on the Google Play store) on their smartphone that records their day-to-day physiological and behavioural status associated with use of the hand (smartphone touchscreen). The study will examine behaviour changes before and after surgery, and how this change in measured behaviour with the smartphone relates to the neuropsychological examination and quantification of brain damage on imaging studies (MRI).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Martin N Stienen, MD, FEBNS
- Phone Number: 1111 +41-44-255
- Email: mnstienen@gmail.com
Study Contact Backup
- Name: Luca Regli, MD
- Phone Number: 1111 +41-44-255
- Email: luca.regli@usz.ch
Study Locations
-
-
-
Zurich, Switzerland, 8091
- Recruiting
- University Hospital Zurich
-
Contact:
- Martin N Stienen, MD, FEBNS
- Phone Number: 1111 +4144255
- Email: mnstienen@gmail.com
-
Sub-Investigator:
- Kevin Akeret, MD
-
Sub-Investigator:
- Flavio Vasella, MD
-
Sub-Investigator:
- Olivia Geisseler, PhD
-
Sub-Investigator:
- Noemi Dannecker, MSc
-
Sub-Investigator:
- Peter Brugger, PhD
-
Sub-Investigator:
- Oliver Bozinov, MD
-
Sub-Investigator:
- Niklaus Krayenbühl, MD
-
Sub-Investigator:
- Lennart Stieglitz, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Consent of the patient
- Age: ≥18
- Fluent language skills in German
- Patient is scheduled for either maximum safe resection of a brain tumour/AVM via craniotomy or VP-shunting for hydrocephalus
- Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months
- Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)
Exclusion Criteria:
- Presence of known neurologic or psychiatric disease other than brain tumour/AVM or hydrocephalus that can potentially influence the performance of a patient while using the smartphone (e.g. dementia, multiple sclerosis, bipolar disorder)
- Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living abroad)
- Patients enrolled in a different clinical trial according to KlinV (participation in another research project according to HFV is allowed, if this is not a burden to the patient)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients With Brain Tumors/AVMs
Patients with a brain tumour/AVM scheduled for maximum safe resection via craniotomy. Participants fulfilling all of the following inclusion criteria are eligible for the study:
|
There is no study-specific intervention
|
Patients With Hydrocephalus
Patients with hydrocephalus scheduled for VP-shunting Participants fulfilling all of the following inclusion criteria are eligible for the study:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pattern of smartphone-assessed day-to-day behaviour
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the primary endpoint, the patterns of smartphone-assessed day-to-day behaviour in the time period before the operation (day -7 until day 0) will be graphically illustrated and compared for obvious differences to the behaviour in the first postoperative week (+7 days) and in the week before the postoperative consultation at three months after the operation.
Towards this we shall employ exhaustive statistical and numerical methods that are typical of complex systems research.
This includes comparing the patterns in defined parameter space, clustering of patterns dependent on the diseased state and defining new parameter spaces where the data conforms to the working hypothesis.
|
One week before surgery until the follow-up three months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
KPS
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the secondary endpoints, several scores have to be correlated to the complex data generated.
Towards this we shall deploy large-scale multivariate approaches that span various time scales - from ms to hours, and that are conducted using sweeping windows across the entire period recording.
By using statistical clustering methods, we shall correct for multiple comparison when inferring our data.
|
One week before surgery until the follow-up three months after surgery
|
NIHSS
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the secondary endpoints, several scores have to be correlated to the complex data generated.
Towards this we shall deploy large-scale multivariate approaches that span various time scales - from ms to hours, and that are conducted using sweeping windows across the entire period recording.
By using statistical clustering methods, we shall correct for multiple comparison when inferring our data.
|
One week before surgery until the follow-up three months after surgery
|
MoCA score
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the secondary endpoints, several scores have to be correlated to the complex data generated.
Towards this we shall deploy large-scale multivariate approaches that span various time scales - from ms to hours, and that are conducted using sweeping windows across the entire period recording.
By using statistical clustering methods, we shall correct for multiple comparison when inferring our data.
|
One week before surgery until the follow-up three months after surgery
|
Domain-specific z-scores of neuropsychological functioning, age-, sex- and education-adjusted
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the secondary endpoints, several scores have to be correlated to the complex data generated.
Towards this we shall deploy large-scale multivariate approaches that span various time scales - from ms to hours, and that are conducted using sweeping windows across the entire period recording.
By using statistical clustering methods, we shall correct for multiple comparison when inferring our data.
|
One week before surgery until the follow-up three months after surgery
|
For patients with a brain tumour, location of the lesion, as determined on MRI imaging
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the secondary endpoints, several scores have to be correlated to the complex data generated.
Towards this we shall deploy large-scale multivariate approaches that span various time scales - from ms to hours, and that are conducted using sweeping windows across the entire period recording.
By using statistical clustering methods, we shall correct for multiple comparison when inferring our data.
|
One week before surgery until the follow-up three months after surgery
|
For patients with a brain tumour, the size of the lesion
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the secondary endpoints, several scores have to be correlated to the complex data generated.
Towards this we shall deploy large-scale multivariate approaches that span various time scales - from ms to hours, and that are conducted using sweeping windows across the entire period recording.
By using statistical clustering methods, we shall correct for multiple comparison when inferring our data.
|
One week before surgery until the follow-up three months after surgery
|
For patients with a brain tumour, the degree of affected brain tissue as seen on early (within 5 days) or late postoperative MRI (3 months)
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the secondary endpoints, several scores have to be correlated to the complex data generated.
Towards this we shall deploy large-scale multivariate approaches that span various time scales - from ms to hours, and that are conducted using sweeping windows across the entire period recording.
By using statistical clustering methods, we shall correct for multiple comparison when inferring our data.
|
One week before surgery until the follow-up three months after surgery
|
For patients with hydrocephalus, ventricular enlargement, as determined on MRI imaging, according to the Evans index (=A/E); Third ventricle index (= C/E); Cella media index (=D/F); Ventricular score (=(A+B+C+D)/E x 100)
Time Frame: One week before surgery until the follow-up three months after surgery
|
For the secondary endpoints, several scores have to be correlated to the complex data generated.
Towards this we shall deploy large-scale multivariate approaches that span various time scales - from ms to hours, and that are conducted using sweeping windows across the entire period recording.
By using statistical clustering methods, we shall correct for multiple comparison when inferring our data.
|
One week before surgery until the follow-up three months after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General remarks
Time Frame: One week before surgery until the follow-up three months after surgery
|
For each individual patient, the secondary endpoints before and after surgery will be compared (in-subject differences) and related to the patterns of smartphone-assessed day-to-day behaviour. In general, patients with brain tumours and patients with hydrocephalus are analysed separately. As this study is a proof-of-concept study, no formal sample size calculation is performed. |
One week before surgery until the follow-up three months after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Peter Brugger, PhD, Neuropsychological Unit, Department of Neurology, University Hospital Zurich, Switzerland
- Study Director: Arko Ghosh, PhD, Faculty of Social and Behavioural Sciences, Leiden University, Netherlands
- Study Chair: Luca Regli, MD, Department of Neurosurgery, University Hospital Zurich
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Cardiovascular Abnormalities
- Vascular Malformations
- Congenital Abnormalities
- Brain Neoplasms
- Arteriovenous Malformations
- Hydrocephalus
Other Study ID Numbers
- BASEC 2018-00395
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Tumor
-
University of California, San FranciscoGilead SciencesSuspendedBrain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, PediatricUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...CNOG-MC001 Collaborative GroupCompletedPediatric Brain Tumor | Malignant Brain Tumor | Tumors, Central Nervous System | Benign Brain TumorChina
-
Technical University of MunichRecruiting
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
Washington University School of MedicineNot yet recruitingBrain Tumor, PrimaryUnited States
-
GT Medical Technologies, Inc.RecruitingBrain Tumor | Brain Tumor, Recurrent | Brain Tumor, Primary | Brain Tumor - Metastatic | Brain Tumor, Adult: Glioblastoma | Brain Tumor, Adult MeningiomaUnited States
-
The Hospital for Sick ChildrenPediatric Oncology Group of OntarioCompletedChildhood Brain TumorCanada
-
Ohio State University Comprehensive Cancer CenterCompletedAdult Brain TumorUnited States
-
Lawson Health Research InstituteCompletedBrain Tumor | Brain Neoplasm | Tumor, Brain | Neoplasm, Supratentorial | Tumor, SupratentorialCanada
Clinical Trials on There is no study-specific intervention
-
Washington University School of MedicineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Christiana Care Health ServicesAmerican Society for Metabolic and Bariatric SurgeryCompleted
-
Public Health Service South LimburgMaastricht University; National Institute for Public Health and the Environment... and other collaboratorsEnrolling by invitation
-
Hvidovre University HospitalRecruitingSubacromial Impingement Syndrome | Subacromial Pain Syndrome | Subacromial ImpingementDenmark
-
Queens College, The City University of New YorkNational Cancer Institute (NCI)UnknownMortality
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOcular Hypertension | Glaucoma, Open-AngleCanada
-
University of GeorgiaCompletedHuman PapillomavirusUnited States
-
KU LeuvenCompletedCongenital Heart DiseaseBotswana, United States, Korea, Republic of, Belgium, Sweden, France, Switzerland, Denmark, Pakistan, Norway, Taiwan, Malta, Brazil, Bulgaria, India, Austria, Argentina, Australia, Cameroon, Canada, Chile, Colombia, Ethiopia, Greece, Italy and more
-
Maimónides Biomedical Research Institute of CórdobaCompletedInvasive FusariosisSpain
-
ProgenaBiomeRecruitingGastrointestinal Microbiome | Gut MicrobiomeUnited States